EXPRESSION PATTERNS OF MULTIDRUG-RESISTANCE (MDRl), GLUTATHIONE-S-TRANSFERASE-T (GST-T) AND DNA TOPOISOMERASE MULTIDRUG RESISTANCE-ASSOCIATED PROTEIN (MRP), I1 (TOP0 11) GENES IN RENAL CELL CARCINOMAS AND NORMAL KIDNEY

Purpose: Expression levels of the multidrug-resistance (mdrl), multidrug resistance-associated protein (MRP), glutathione-S-transferase-.rr (GST-.rr) and DNA topoisomerase I1 (Topo 11) genes in normal kidney and renal cell carcinomas were analyzed to study the complexity of the roles of these genes. Materials and Methods: The reverse transcription-polymerase chain reaction (RT-PCR) assay was used with p2 microglobulin (p2 m) as the internal control. Results: In normal kidneys, the expression levels of the 4 genes in individual normal kidney samples correlated significantly with one another. Comparisons of the expression levels between normal kidneys and renal cell carcinomas showed that only the mean MRP gene expression level was higher in renal cell carcinomas than in normal kidneys (p = 0.018). The expression patterns of the 4 genes in renal cell carcinomas differed markedly for nonpapillary and papillary tumors. The mean MRPIP, m ratio for the papillary type was significantly lower than that for the nonpapillary alveolar type carcinoma (p = 0.004). The 4 genes showed moderate positive correlations with one another in alveolar type renal carcinoma similar to the correlations observed in normal kidneys. In contrast, in papillary type, MRP expression was inversely correlated with mdrl and Top0 I1 expression. Conclusion: Differences in cytogenetic changes, origins and natural histories between papillary and nonpapillary carcinoma may be associated with these distinct expression patterns of the resistance-related genes. Further study is required to clarify whether the differences in the expression patterns between these 2 structural types of carcinoma affect their chemosensitivities and clinical outcomes.

[1]  G. Kovacs,et al.  Diagnosis and prognosis of renal-cell tumors: a molecular approach , 1995, World Journal of Urology.

[2]  G. Kovacs The value of molecular genetic analysis in the diagnosis and prognosis of renal cell tumours , 2004, World Journal of Urology.

[3]  O. Yoshida,et al.  Comparison of multidrug resistance gene expression levels with malignant potentials and influence of chemotherapy in urothelial cancers. , 1995, International journal of urology : official journal of the Japanese Urological Association.

[4]  Wun-Jae Kim,et al.  Multidrug Resistance‐associated Protein‐mediated Multidrug Resistance Modulated by Cyclosporin A in a Human Bladder Cancer Cell Line , 1995, Japanese journal of cancer research : Gann.

[5]  M. Haber,et al.  Expression of the multidrug resistance-associated protein (MRP) gene correlates with amplification and overexpression of the N-myc oncogene in childhood neuroblastoma. , 1994, Cancer research.

[6]  J. Buer,et al.  Immunocytochemical detection of P-glycoprotein: initial expression correlates with survival in renal cell carcinoma patients. , 1994, Oncology.

[7]  J. Schneider,et al.  P-glycoprotein, HER-2/neu, and mutant p53 expression in human gynecologic tumors. , 1994, Journal of the National Cancer Institute.

[8]  H. Tashiro,et al.  Expression of multidrug resistance gene and localization of P-glycoprotein in human primary ovarian cancer. , 1994, Cancer research.

[9]  K. Kohno,et al.  Enhanced expression of the DNA topoisomerase II gene in response to heat shock stress in human epidermoid cancer KB cells. , 1993, Cancer research.

[10]  L. Füzesi,et al.  Collecting duct carcinoma: cytogenetic characterization , 1992, Histopathology.

[11]  R. McMahon,et al.  Renal carcinoma in patients undergoing nephrectomy: analysis of survival and prognostic factors. , 1992, British journal of urology.

[12]  M. Volm,et al.  Immunohistochemical detection of P glycoprotein, glutathione S transferase and DNA topoisomerase II in human tumors. , 1992, Oncology.

[13]  J. Kuszak,et al.  Relationship of the expression of the multidrug resistance gene product (P-glycoprotein) in human colon carcinoma to local tumor aggressiveness and lymph node metastasis. , 1991, Cancer research.

[14]  A. Gazdar,et al.  Quantitative analysis of MDR1 (multidrug resistance) gene expression in human tumors by polymerase chain reaction. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[15]  S. de Jong,et al.  Reduced DNA topoisomerase II activity and drug-induced DNA cleavage activity in an adriamycin-resistant human small cell lung carcinoma cell line. , 1990, Cancer research.

[16]  I. Pastan,et al.  Heat shock and arsenite increase expression of the multidrug resistance (MDR1) gene in human renal carcinoma cells. , 1990, The Journal of biological chemistry.

[17]  I. Pastan,et al.  The multidrug transporter, a double-edged sword. , 1988, The Journal of biological chemistry.

[18]  T. Rushmore,et al.  Carcinogen-induced mdr overexpression is associated with xenobiotic resistance in rat preneoplastic liver nodules and hepatocellular carcinomas. , 1987, Proceedings of the National Academy of Sciences of the United States of America.

[19]  P. Chomczyński,et al.  Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. , 1987, Analytical biochemistry.

[20]  A. Tulpule,et al.  Overexpression of a novel anionic glutathione transferase in multidrug-resistant human breast cancer cells. , 1986, The Journal of biological chemistry.